Free Trial

Stevanato Group (NYSE:STVN) Shares Down 7.8% - What's Next?

Stevanato Group logo with Medical background
Remove Ads

Stevanato Group S.p.A. (NYSE:STVN - Get Free Report)'s share price dropped 7.8% during mid-day trading on Tuesday . The stock traded as low as €20.71 ($22.51) and last traded at €20.83 ($22.64). Approximately 76,087 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 345,984 shares. The stock had previously closed at €22.60 ($24.57).

Wall Street Analysts Forecast Growth

STVN has been the subject of a number of research reports. Bank of America boosted their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Morgan Stanley reaffirmed an "equal weight" rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. UBS Group cut their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday. William Blair reiterated an "outperform" rating on shares of Stevanato Group in a research note on Friday. Finally, Wolfe Research started coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an "outperform" rating and a $28.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of €27.75 ($30.16).

View Our Latest Stock Report on Stevanato Group

Stevanato Group Price Performance

The company has a market cap of $6.42 billion, a PE ratio of 45.11, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60. The stock has a fifty day simple moving average of €21.40 and a two-hundred day simple moving average of €20.57. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Remove Ads

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. On average, equities analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Institutional Trading of Stevanato Group

Institutional investors have recently added to or reduced their stakes in the stock. Van Berkom & Associates Inc. acquired a new stake in shares of Stevanato Group during the 4th quarter valued at approximately $39,000. Johnson Financial Group Inc. acquired a new position in Stevanato Group during the fourth quarter worth $41,000. Wells Fargo & Company MN boosted its position in Stevanato Group by 680.3% during the fourth quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock worth $71,000 after purchasing an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after purchasing an additional 5,291 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Stevanato Group by 202.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock valued at $162,000 after buying an additional 4,965 shares in the last quarter.

Stevanato Group Company Profile

(Get Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stevanato Group Right Now?

Before you consider Stevanato Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.

While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

These Are the 3 Stocks Most Likely to SPLIT in 2025

These Are the 3 Stocks Most Likely to SPLIT in 2025

MarketBeat analyst Thomas Hughes breaks down why companies split their stock and reveals his top three picks most likely to split next year.

Related Videos

Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Elon Musk’s First 100 Days of DOGE: 3 AI Stocks Ready to Soar
5 Stocks to BUY NOW in February 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads